bluuebunny/crossref_metadata_2025_split huggingface dataset:
ANALISIS FAKTOR YANG BERPENGARUH TERHADAP PEMBENGKAKAN BIAYA SELAMA PELAKSANAAN PROYEK DI MASA PANDEMI COVID-19 PADA PELAKU JASA KONSTRUKSI SKALA KECIL DI BALI
Authors: Laksmi Ida Ayu Cri Vinantya , Jawat I Wayan , Armaeni Ni Komang 
Published: October 2022

Pandemi virus Covid-19 yang melanda Indonesia, khususnya Bali sangat berdampak pada kehidupan masyarakat. Hal tersebut memberikan dampak pada beberapa sektor, mulai dari sektor kesehatan, ekonomi, pendidikan, pariwisata termasuk sektor pembangunan. Wabah Corona memaksa semua negara untuk merevisi perencanaan pembangunan yang telah dicanangkan. Target disesuaikan secara realistis, asumsi diubah sesuai keadaan sekarang, dan prioritas program jangka pendek dialihkan sebagian besar untuk mengatasi pandemi Covid-19. Dalam rangka percepatan pembangunan untuk memulihkan kondisi perekonomian, beberapa pelaku jasa konstruksi skala kecil masih bisa melaksanakan pembangunan meskipun harus mengalami beberapa kendala. Selama melaksanakan pembangunan di tengah pandemi, tentunya ada beberapa biaya yang mengalami perubahan yang cukup signifikan bahkan dapat menyebabkan pembengkakan biaya. Pembengkakan biaya proyek konstruksi sangat tergantung dari beberapa faktor, baik faktor internal maupun faktor eksternal proyek. Beberapa factor yang sangat berpengaruh dalam pembengkakan biaya selama pelaksanaan proyek yang dilakukan oleh pelaku jasa kontruksi skala kecil di masa pandemi Covid-19, antara lain: estimasi biaya tidak tepat (9,33%), kesalahan dalam memilih metode pengerjaan (8,84%), produktivitas tenaga kerja yang rendah (8,15%), kesalahan dimensi/ukuran pekerjaan dalam pelaksanaan (8,14%), sering terjadi penundaan pekerjaan (8,04%), keterlambatan jadwal karena pengaruh cuaca (8,00%), adanya kenaikan harga material (7,94%), harga/sewa peralatan yang tinggi (7,67%), terlambat/kekurangan bahan dan material (7,31%), kerusakan material (6,81%), spesifikasi bahan yang tidak cocok (6,52%), dan cara pembayaran yang tidak tepat waktu (6,26%).
Providing Health Education as an Effort to Improve Knowledge and Prevention of COVID-19 for Persons with Disabilities, PPDMS Social Institutions, Nglipar, Gunungkidul
Authors: Widagdo The Maria Meiwati , Manus Widya Christine , Frista Frista , Indonesia Matahari Bunga 
Published: October 2022

People with disabilities are vulnerable to being infected with the COVID-19 virus. The COVID-19 pandemic has had an impact on human life, including the health of people with disabilities. The government makes various policies and programs in an effort to prevent the spread of COVID-19, but their implementation is still challenging for people with disabilities. This community service program was carried out in collaboration with Mitra Sejahtera Disability Empowerment Center (PPDMS), an organization empowering people with disabilities in Gunungkidul Regency. Empowerment of people with disabilities was carried out using 'community control' principle in which the community has the control in making decisions regarding the problems they face so that they can adopt a ‘new normal’ lifestyle because of their knowledge. The principle of 'community control' was applied by providing education about COVID-19 situation in Indonesia, the symptoms and signs of COVID-19 infection, wash hands, proper cough etiquette, how to use masks, food and lifestyle that can prevent COVID-19 transmission, as well as about the benefits of COVID-19 vaccination. Education was given with a presentation followed by discussion. Evaluation was carried out quantitatively and qualitatively. Quantitative evaluation using pretest and post-test showed an increase in knowledge. Qualitative evaluation using FGD indicated changes in attitudes and behavior that support the adoption of ‘new normal’ lifestyle to prevent transmission of COVID-19. People with disabilities who have received education disseminate the information obtained to other people with disabilities, resulted in multiplication effect of this empowerment program for people with disabilities.
Medicine Consumption Reminder and Monitoring Application for Patients with Leprosy Disease
Authors: Irawan Paulus Lucky Tirma , Hartanto Calvin Brylland Septhanya , Kelana Oesman Hendra 
Published: October 2022

Leprosy or also known as Hansen's disease (HD) or Morbius Hansen's disease (MHD) caused by the bacterium Mycobacterium leprae. The symptoms of leprosy are hardly identified. In fact, some symptoms only can be identified after 20-30 years. Recently, the advent of multidrug therapy (MDT) and the use of anti-inflammatory therapies have given substantial improvements in long-term health outcomes for patients diagnosed with leprosy. However, the medication was a time consuming. Healthy behavior in the management of leprosy treatment requires discipline in taking leprosy medication. On the contrary, poor treatment management will lead to permantent consequnces of disability and deformity. Various Android-based applications have been developed by programmers. Smartphone technology is expected to help patients taking medication in supervising and reminding. In addition, through the cloud based technology the mobile application is expected to be solution as medium of information and communication for every stake holder in dealing with leprosy patients. This research involves a series of software development processes which are divided into several phases. Starting with the identification of the problem, moving on to the design of the application and the API service, to the development and testing of the application using a variety of test scenarios, and concluding with the documentation process. Both the functionality and the design were tested using the User Experience Questionnaire (UEQ) and black-box testing. Based on the outcomes of black box testing, the app's functionality work without any issues. The UEQ results show that novelty (Good), stimulation (Good), efficiency (Good), reliability (Above Average), perspicuity (Above Average), and beauty (Good) are all positive (Above Average). According to the UEQ results, the application received the highest efficiency level rating of 1.75, which indicates that it is regarded as having good consumption efficiency and being usable.
Kinetics of monocyte subpopulations during experimental cerebral malaria and its resolution in a model of late chloroquine treatment
Authors: Royo Jade , Camara Aissata , Bertrand Benedicte , Batigne Philippe , Coste Agnes , Pipy Bernard , Aubouy Agnes ,   the NeuroCM Group
Published: October 2022

Cerebral malaria (CM) is one of the most severe forms of malaria and is a neuropathology that can lead to death. Monocytes have been shown to accumulate in the brain microvasculature at the onset of neurological symptoms during CM. Monocytes have a remarkable ability to adapt their function to their microenvironment from pro-inflammatory to resolving activities. This study aimed to describe the behavior of monocyte subpopulations during infection and its resolution. C57BL/6 mice were infected with the Plasmodium berghei ANKA strain and treated or not with chloroquine (CQ) on the first day of the onset of neurological symptoms (day 6) for 4 days and followed until day 12 to mimic neuroinflammation and its resolution during experimental CM. Ly6C monocyte subpopulations were identified by flow cytometry of cells from the spleen, peripheral blood, and brain and then quantified and characterized at different time points. In the brain, the Ly6Cint and Ly6Clow monocytes were associated with neuroinflammation, while Ly6Chi and Ly6Cint were mobilized from the peripheral blood to the brain for resolution. During neuroinflammation, CD36 and CD163 were both involved via splenic monocytes, whereas our results suggest that the low CD36 expression in the brain during the neuroinflammation phase was due to degradation. The resolution phase was characterized by increased expressions of CD36 and CD163 in blood Ly6Clow monocytes, a higher expression of CD36 in the microglia, and restored high expression levels of CD163 in Ly6Chi monocytes localized in the brain. Thus, our results suggest that increasing the expressions of CD36 and CD163 specifically in the brain during the neuroinflammatory phase contributes to its resolution.
Combined effects of physical activity and sedentary behavior on all-cause mortality in heart failure patients: A cohort study of national health and nutrition examination survey analysis
Authors: Zhu Yunhui , Chen Zhebin , Chen Songzan , Fu Guosheng , Wang Yao 
Published: October 2022

BackgroundPhysical activity and sedentary behavior are independently related to the risk of cardiovascular disease. Physical activity is recognized as having a protective effect, while being sedentary seems to be adverse. Nonetheless, the interactions between physical activity and sedentary behavior and the combined effect on the prognosis of heart failure patients remain unclear.Methods and resultsThis cohort study included 886 heart failure patients from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. Physical activity and sedentary behavior were assessed by the NHANES questionnaires. The all-caused deaths of enrolled subjects were identified from National Death Index (NDI) database. During a median follow-up of 51 months, 321 (36.2%) deaths from any causes occurred. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence interval (CI) for the all-cause mortality in heart failure patients associated with physical activity and sedentary behavior. Physical activity was independently associated with lower mortality [HR = 0.51, 95% CI (0.38-0.68), p &lt; 0.001] and sedentary behavior was associated with adverse prognosis [HR = 1.79, 95% CI (1.41–2.28), p &lt; 0.001]. Kaplan–Meier survival curve showed that physical activity appeared to attenuate the negative consequences of SB, while sedentary behavior increased the all-cause mortality, particularly those without physical activity.ConclusionPhysical activity has a protective effect on HF patients’ prognosis, particularly those with sedentary behavior. Sedentary behavior independently exhibited a negative association in populations without physical activity, while it does not increase mortality in those with moderate physical activity.
Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials
Authors: Gong Chen , Shen Shi-Chun , Zhang Ke , Zhou Lei , Shen Jun-Jie , Zhao Jia-Ying , Ding Sheng-Gang , Ma Li-kun , Gao Hui 
Published: October 2022

BackgroundThe clinical benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors for preventing and treating cardiovascular events remains controversial. We aimed to study the effect of SGLT2 inhibitors on cardiovascular outcomes and safety events, giving particular attention to the benefits in subgroups of patients with different diseases.MethodRandomized controlled trials (RCTs) reporting cardiovascular outcomes following the administration of SGLT2 inhibitors and placebo were included in this study. Cardiovascular outcomes included all-cause death, major adverse cardiovascular events (MACEs), cardiovascular (CV) death, myocardial infarction (MI), stroke, and hospitalization for heart failure (HHF). We also focused on the cardiovascular benefits of SGLT2 inhibitor application in subgroups of patients with different diseases, including type 2 diabetes (T2D), heart failure (HF), high risk of atherosclerotic cardiovascular disease (ACD), diagnosed ACD, and chronic kidney disease (CKD). Safety events associated with SGLT2 inhibitors, including acute kidney injury (AKI), diabetic ketoacidosis (DKA), hypoglycemia, urinary tract infection, thromboembolic event, bone fracture, volume depletion, and amputation, were also reported.ResultsThis meta-analysis included 15 RCTs with 78,212 participants. SGLT2 inhibitors reduced the risk of all-cause death (RR 0.89; 95% CI: 0.85–0.94; I2 = 32%; p &lt; 0.01), CV death (RR 0.87; 95% CI: 0.82–0.93; I2 = 11%; p &lt; 0.01), MACEs (RR 0.89; 95% CI: 0.84–0.94; I2 = 46%; p &lt; 0.01), HHF (RR 0.70; 95% CI: 0.66–0.74; I2 = 0%; p &lt; 0.01), and AKI (RR 0.81; 95% CI: 0.73–0.90; I2 = 0%; p &lt; 0.01) but increased the risk of DKA (RR 2.56; 95% CI: 1.72–3.80; I2 = 0%; p &lt; 0.01). However, no apparent benefit in MI and stroke was observed between the SGLT2 inhibitor and control groups. SGLT2 inhibitors reduced the risk of all-cause death, MACEs, CV death, and HHF in diabetic patients; reduced the risk of all-cause death, MACEs, CV death, MI, and HHF in primary prevention; reduced the risk of all-cause death, CV death, and HHF in patients with ACD and HF; and reduced the risk of MACEs, CV death, and HHF in patients with CKD.ConclusionSGLT2 inhibitors have a positive effect in reducing the risk of all-cause death, CV death, MACE, HHF, and AKI and increasing the risk of DKA. The application of SGLT2 inhibitors in the primary prevention of ACD also has certain clinical benefits in reducing MI.Systematic review registration[https://www.crd.york.ac.uk/prospero/], identifier [CRD42022306490].
Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma
Authors: Baldi Salem , He Yun , Ivanov Igor , Khamgan Hassan , Safi Mohammed , Alradhi Mohammed , Shopit Abdullah , Al-Danakh Abdullah , Al-Nusaif Murad , Gao Yaping , Tian Hui 
Published: October 2022

Background and Objective: Understanding the tumor microenvironment (TME) and immune cell infiltration (ICI) may help guide immunotherapy efforts for colon cancer (COAD). However, whether ARID1B is truly regulated by hypermethylation or linked to immune infiltration remains unknown. The current work focused on the ARID1B gene expression and methylation in COAD, as well as its relation with ICI.Methods and Results: Multiple tools based on TCGA were used to analyze the differences in the expression of the ARID1B gene, DNA methylation, and its association with various clinicopathological features, somatic mutations, copy number variation, and the prognosis of patients with COAD. According to the analysis results, patients with high mRNA, low methylation levels showed better overall survival than patients with low mRNA, high methylation levels. The correlation analysis of immune cell infiltration and immune checkpoint gene expression showed that the infiltration rates of the main ICI subtypes, cancer-associated fibroblast, and myeloid cells were significantly enriched and correlated with ARID1B in COAD. An association between ARID1B expression and immune infiltration in COAD was found by correlating ICI indicators with ARID1B expression in the immune cell composition of the COAD microenvironment. Notably, M2 chemokines were related to ARID1B expression, while M1 chemokines were not.Conclusion: This study provided evidence that ARID1B may have a role in the pathogenesis of COAD. The specific underlying mechanisms that could be responsible for ARID1B’s downregulation in COAD will need to be investigated in the future.
An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer
Authors: Wang Ke-wei , Wang Mei-dan , Li Zi-xi , Hu Ben-shun , Wu Jun-jie , Yuan Zheng-dong , Wu Xiao-long , Yuan Qin-fang , Yuan Feng-lai 
Published: October 2022

ObjectiveThe aim of the study was to propose a signature based on genes associated with antigen processing and presentation (APscore) to predict prognosis and response to immune checkpoint inhibitors (ICIs) in advanced gastric cancer (aGC).BackgroundHow antigen presentation-related genes affected the immunotherapy response and whether they could predict the clinical outcomes of the immune checkpoint inhibitor (ICI) in aGC remain largely unknown.MethodsIn this study, an aGC cohort (Kim cohort, RNAseq, N=45) treated by ICIs, and 467 aGC patients from seven cohorts were conducted to investigate the value of the APscore predicting the prognosis and response to ICIs. Subsequently, the associations of the APscore with the tumor microenvironment (TME), molecular characteristics, clinical features, and somatic mutation variants in aGC were assessed. The area under the receiver operating characteristic curve (AUROC) of the APscore was analyzed to estimate response to ICIs. Cox regression or Log-rank test was used to estimate the prognosis of aGC patients.ResultsThe APscore constructed by principal component analysis algorithms was an effective predictive biomarker of the response to ICIs in the Kim cohort and 467 aGC patients (Kim: AUC =0.85, 95% CI: 0.69–1.00; 467 aGC: AUC =0.69, 95% CI: 0.63–0.74). The APscore also was a prognostic biomarker in 467 aGC patients (HR=1.73, 95% CI: 1.21−2.46). Inhibitory immunity, decreased TMB and low stromal scores were observed in the high APscore group, while activation of immunity, increased TMB, and high stromal scores were observed in the low APscore group. Next, we evaluated the value of several central genes in predicting the prognosis and response to ICIs in aGC patients, and verified them using immunogenic, transcriptomic, genomic, and multi-omics methods. Lastly, a predictive model built successfully discriminated patients with vs. without immunotherapy response and predicted the survival of aGC patients.ConclusionsThe APscore was a new biomarker for identifying high-risk aGC patients and patients with responses to ICIs. Exploration of the APscore and hub genes in multi-omics GC data may guide treatment decisions.
The supervision and multi-sectoral guarantee mechanism of the global marine sulphur limit—assessment from Chinese shipping industry
Authors: Liu Xiaofei 
Published: October 2022

To significantly reduce sulfur oxides emissions from fossil fuel-powered ships, reduce air pollution in ports and slow ocean acidification, the International Maritime Organization (IMO) has imposed the new 0.50%m/m limit (reduced from 3.50%m/m in the past) on sulphur in ships’ fuel oil. This has given rise to a host of issues regarding fuel replenishment operations, safe operation management, maritime regulation, and coordinated governance of air and climate. In response to ocean acidification and climate change, regulations on the use of low-sulfur oil or alternative fuels by ships greatly reduce sulfur oxide emissions, but have no significant impact on reducing greenhouse gas emissions. In fact, the refining process for low-sulfur fuels and the use of the gas cleaning system on ships both increase energy consumption and carbon dioxide emissions. To ensure the decarbonization process of shipping industry, there is an urgent need for a conceptual change in global ocean governance so as to promote the coordinated governance of air pollution and climate change. China’s conception of “a maritime community with a shared future” provides a new model for global ocean governance. The Chinese government has formulated regulations at different levels to promote the coordinated management of atmospheric pollutants and greenhouse gas emissions. Regarding supervision of sulfur oxide emissions from ships, this study proposes to build a multi-department collaborative supervision mechanism from marine fuel life cycle to enhance sulfur oxide monitoring and risk control capabilities. Specific measures of the proposed supervision mechanism include: the joint supervision of compliant fuel supply, the compliant fuel information disclosure platform, a joint law enforcement mechanism for atmospheric pollution, the ability of intelligent ship exhaust monitoring, and the construction of port power infrastructure.
A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy
Authors: Ye Zhen , Huang Qinfeng , She Yingqi , Hu Yu , Wu Mingquan , Qin Kaihua , Li Linzhen , Zhang Chuantao , Zuo Xiaohong , Wei Ailing , Mao Dewen , Ye Qiaobo 
Published: October 2022

BackgroundHepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial for the treatment of cirrhosis. Hence, a systematic review and clinical evidence assessment of DHZCP-based therapy should be performed, and clinical recommendations based on its efficacy for the treatment of hepatic fibrosis should be generated. With respect to potential indicators, the comparative value of the hepatic function, spleen thickness, and portal vein internal diameter should be evaluated.Materials and methodsPubMed, the Excerpta Medica Database, the Cochrane Library, the Web of Science, the WanFang Database, the Chinese Scientific Journal Database, and the Chinese National Knowledge Infrastructure database were searched to identify clinical trials. Three subgroup analyses were performed based on the stage of disease, medication use, and the course of treatment. Statistical analyses were performed using Review Manager 5.4.ResultsA total of 18 studies including 1,494 patients were evaluated. The DHZCP-based therapy was effective in reducing the plasma levels of hyaluronic acid, and laminin, procollagen III, and IV collagen were also reduced irrespective of the hepatitis stage or the presence of hepatic cirrhosis. Abnormalities in alanine aminotransferase, aspartate aminotransferase, albumin, and total bilirubin were reversed. A 6-month course of treatment was the most beneficial DHZCP-based therapy regimen. Alanine aminotransferase improvement was more obvious in patients with cirrhosis, and alanine aminotransferase was reduced significantly in patients with hepatic cirrhosis. With respect to pharmacological mechanisms, DHZCP-based therapy could inhibit hepatic stellate cell growth and activation, reduce inflammation, and prevent extracellular matrix formation. Hepatic portal hypertension and splenomegaly were ameliorated significantly in the DHZCP-based therapy group.ConclusionDahuang Zhechong pill-based therapy has demonstrated efficacy as a treatment for hepatic fibrosis and cirrhosis. A 6-month course of treatment is the recommended option for DHZCP-based therapy in clinical practice. The combination of DHZCP-based therapy and entecavir is a favorable treatment for hepatic cirrhosis.